The discovery of the pressor effect of DOPS and its blunting by decarboxylase inhibitors

Journal of Neural Transmission, Supplement

Volumn , Issue 70, 2006, Pages 477-484

  Kaufmann, H ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 THREO DIHYDROXYPHENYLSERINE; AROMATIC LEVO AMINO ACID DECARBOXYLASE; CARBIDOPA; DECARBOXYLASE INHIBITOR; DOPA; DOPAMINE BETA MONOOXYGENASE; NORADRENALIN; SERINE DERIVATIVE; UNCLASSIFIED DRUG;

AUTONOMIC DYSFUNCTION; BLOOD BRAIN BARRIER; CONFERENCE PAPER; DRUG DISTRIBUTION; DRUG EFFECT; DRUG MECHANISM; FAMILIAL AMYLOID POLYNEUROPATHY; HUMAN; NORADRENALIN RELEASE; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PRESSOR RESPONSE; PRIORITY JOURNAL;

EID: 33750322455     PISSN: 03036995     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-211-45295-0_71     Document Type: Conference Paper

References (25)

1. Araki H, Tanaka C, et al. (1981) Pressor effect of L-threo-3,4- dihydroxyphenylserine in rats. J Pharm Pharmacol 33(12): 772-777
2. Bartholini J, Constantinidis J, et al. (1975) The stereoisomers of 3,4-dihydroxyphenylserine as precursors of norepinephrine. J Pharmacol Exp Ther 193(2): 523-532
3. Biaggioni I, Robertson D (1987) Endogenous restoration of noradrenaline by precursor therapy in dopamine-beta-hydroxylase deficiency. Lancet 2(8569): 1170-1172
4. Birkmayer W, Birkmayer G, et al. (1983) DL-3,4-threo-DOPS in Parkinson's disease: effects on orthostatic hypotension and dizziness. J Neural Transm 58(3-4): 305-313
5. Blaschko H, Burn JH, et al. (1950) The formation of noradrenaline from dihydroxyphenylserine. Br J Pharmacol 5(3): 431-437
6. Gibbons CH, Vernino SA, Kaufmann H, Freeman R (2005) DOPS therapy for refractory orthostatic hypotension in autoimmune autonomic neuropathy. Neurology 65: 1104-1106
7. Freeman R, Landsberg L, et al. (1999) The treatment of neurogenic orthostatic hypotension with 3,4-DL-threo-dihydroxyphenylserine: a randomized, placebo-controlled, crossover trial. Neurology 53(9): 2151-2157
8. Goldstein D, Horwitz D, et al. (1983) Plasma 1-[3H]norepinephrine, d-[14C]norepinephrine, and d,1- [3H]isoproterenol kinetics in essential hypertension. J CLIn Invest 72: 1748-1758
9. Goldstein DS, Holmes C, et al. (1997) Sympathetic cardioneuropathy in dysautonomias. N Engl J Med 336(10): 696-702
10. Goldstein DS, Holmes C, et al. (2004) Clinical pharmacokinetics of the norepinephrine precursor L-threo-DOPS in primary chronic autonomic failure. Clin Auton Res 14(6): 363-368
11. Hague K, Lento P, et al. (1997) The distribution of Lewy bodies in pure autonomic failure: autopsy findings and review of the literature. Acta Neuropathol (Berl) 94(2): 192-196
12. Hoeldtke RD, Cilmi KM, et al. (1984) DL-Threo-3,4-dihydroxyphenylserine does not exert a pressor effect in orthostatic hypotension. Clin Pharmacol Ther 36(3): 302-306
13. Inagaki C, Fujiwara H, et al. (1976) Inhibitory effect of (+)threo-3,4-dihydroxy-phenylserine (DOPS) on decarboxylation of (-)threo-dops. Jpn J Pharmacol 26(3): 380-382
14. Kachi T, Iwase S, et al. (1988) Effect of L-threo-3,4- dihydroxyphenylserine on muscle sympathetic nerve activities in Shy-Drager syndrome. Neurology 38(7): 1091-1094
15. Kato T, Karai N, et al. (1987) Studies on the activity of L-threo-3,4-dihydroxyphenylserine (DOPS) as a catecholamine precursor in the brain. Comparison with that of L-dopa. Biochem Pharmacol 36(18): 3051-3057
16. Kaufmann H, Biaggioni I (2003) Autonomic failure in neurodegenerative disorders. Semin Neurol 23(4): 351-363
17. Kaufmann H, Oribe E, et al. (1991) Differential effect of L-threo-3,4-dihydroxyphenylserine in pure autonomic failure and multiple system atrophy with autonomic failure. J Neural Transm (PD Sect) 3(2): 143-148
18. Kaufmann H, Saadia D, et al. (2003) Norepinephrine precursor therapy in neurogenic orthostatic hypotension. Circulation 108(6): 724-728
19. Kim CH, Zabetian CP, et al. (2002) Mutations in the dopamine beta-hydroxylase gene are associated with human norepinephrine deficiency. Am J Med Genet 108(2): 140-147
20. Man in't Veld AJ, Boomsma F, et al. (1987) Effect of unnatural noradrenaline precursor on sympathetic control and orthostatic hypotension in dopamine-beta-hydroxylase defficiency. Lancet 2: 1172-1175
21. Nutt JG, Woodward WR (1986) Levodopa pharmacokinetics and pharmacodynamics in fluctuating parkinsonian patients. Neurology 36(6): 739-744
22. Polinsky RJ, Kopin IJ, et al. (1981) Pharmacologic distinction of different orthostatic hypotension syndromes. Neurology 31(1): 1-7
23. Schmiterlow CG (1951) The formation in vivo of noradrenaline from 3:4-dihydroxyphenylserine (noradrenaline carboxylic acid). Br J Pharmacol 6(1): 127-134
24. Suzuki T, Higa S, et al. (1980) Effect of infused L-threo-3,4- dihydroxyphenylserine on adrenergic activity in patients with familial amyloid polyneuropathy. Eur J Clin Pharmacol 17(6): 429-435
25. Vernino S, Adamski J, et al. (1998) Neuronal nicotinic ACh receptor antibody in subacute autonomic neuropathy and cancer-related syndromes. Neurology 50(6): 1806-1813